Measuring and improving adherence to osteoporosis pharmacotherapy

Current Opinion in Rheumatology

Volumn 22, Issue 4, 2010, Pages 397-403

  Cadarette, Suzanne M ^a   Burden, Andrea M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adherence; Compliance; Measurement; Osteoporosis; Persistence

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ZOLEDRONIC ACID;

COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; HEALTH CARE UTILIZATION; HUMAN; INDIVIDUALIZATION; MEDICAL DECISION MAKING; MEDICAL RESEARCH; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SAFETY; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SELF REPORT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

BONE DENSITY CONSERVATION AGENTS; HUMANS; MEDICATION ADHERENCE; OSTEOPOROSIS;

EID: 77953480734     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32833ac7fe     Document Type: Review

References (51)

1. U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. Rockville, Maryland, USA: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004.
2. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22:465-475.
3. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148:197-213.
4. Khosla S. Increasing options for the treatment of osteoporosis [editorial]. N Engl J Med 2009; 361:818-820.
5. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122:S3-S13.
6. Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bispho-sphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 2009; 10:2303-2315.
7. Imaz I, Zegarra P, Gonzalez-Enriquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010 (in press). doi: 101007/s00198-009-1134-1144
8. Wilkes MM, Navickis RJ, Chan WW, Lewiecki EM. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int 2010; 31:679-688.
9. Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 2010; 86:202-210.
10. Danese MD, Badamgarav E, Bauer DC. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res 2009; 24:1819-1826.
11. Cotte FE, Fautrel B, De Pouvourville G. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med Decis Making 2009; 29:125-139.
12. Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and metaanalysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007; 82:1493-1501.
13. Copher R, Buzinec P, Zarotsky V, et al. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims. Curr Med Res Opin 2010; 26:777-785.
14. Hansen RA, Kim MM, Song L, et al. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother 2009; 43:413-422.
15. Curtis JR, Westfall AO, Allison J, et al. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Safety 2006; 15:710-718.
16. Cramer JA, Silverman SL, Gold DT. Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin 2007; 23:2369-2377.
17. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10:3-12.
18. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11:44-47.
19. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care 2009; 15:457-464.
20. Warriner AH, Curtis JR. Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 2009; 21:356-362.
21. Gold DT, Trinh H, Safi W. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Curr Med Res Opin 2009; 25:1831-1839.
22. Schousboe JT, Dowd BE, Davison ML, Kane RL. Association of medication attitudes with nonpersistence and noncompliance with medication to prevent fractures. Osteoporos Int 2010 (in press). doi:10.1007/s00198-009-1141-5.
23. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008; 2008:329-335.
24. Zambon A, Baio G, Mazzaglia G, et al. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multistate models. Pharmacoepidemiol Drug Saf 2008; 17:260-269.
25. Melo M, Qiu F, Sykora K, et al. Persistence with bisphosphonate therapy in older people. J Am Geriatr Soc 2006; 54:1015-1016.
26. Roughead EE, Ramsay E, Priess K, et al. Medication adherence, first episode duration, overall duration and time without therapy: the example of bispho sphonates. Pharmacoepidemiol Drug Saf 2009; 18:69-75.
27. Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007; 120:251-256.
28. Yu AP, Yu YF, Nichol MB, Gwadry-Sridhar F. Delay in filling the initial prescription for a statin: a potential early indicator of medication nonpersis tence. Clin Ther 2008; 30:761-774.
29. Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 2009; 47:334-341.
30. Mabotuwana T, Warren J, Harrison J, Kenealy T. What can primary care prescribing data tell us about individual adherence to long-term medication? Comparison to pharmacy dispensing data. Pharmacoepidemiol Drug Saf 2009; 18:956-964.
31. Hansen RA, Dusetzina SB, Dominik RC, Gaynes BN. Prescription refill records as a screening tool to identify antidepressant nonadherence. Pharmacoepidemiol Drug Saf 2010; 19:33-37.
32. McHorney CA. The adherence estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin 2009; 25:215-238.
33. McHorney CA, Victor Spain C, Alexander CM, Simmons J. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims. Clin Ther 2009; 31:2584-2607.
34. Lau E, Papaioannou A, Dolovich L, et al. Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician 2008; 54:394-402.
35. Kamatari M, KotoS, OzawaN, et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 2007; 25:302-309.
36. McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on nonadherence to oral bisphosphonates. Curr Med Res Opin 2007; 23:3137-3152.
37. Cadarette SM, Gignac MA, Jaglal SB, et al. Measuring patient perceptions about osteoporosis pharmacotherapy. BMC Res Notes 2009; 2:133.
38. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care 2009; 47:826-834.
39. Giangregorio L, Dolovich L, Cranney A, et al. Osteoporosis risk perceptions among patients who have sustained a fragility fracture. Patient Educ Couns 2009; 74:213-220.
40. Sale JE, Beaton DE, Sujic R, Bogoch ER. 'If it was osteoporosis, I would have really hurt myself.' Ambiguity about osteoporosis and osteoporosis care despite a screening programme to educate fragility fracture patients. J Eval Clin Pract 2010 (in press). doi: JEP11 76 [pii] 10.1111/j.1365-2753.
41. Cadarette SM, Beaton DE, Gignac MAM, et al. Minimal error in self-report of having had DXA, but self-report of its results was poor. J Clin Epidemiol 2007; 60:1306-1311.
42. Kertes J, Dushenat M, Vesterman JL, et al. Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J 2008; 10:207-213.
43. Ideguchi H, Ohno S, Takase K, et al. Outcomes after switching from one bisphosphonate to another in 146 patients at a single university hospital. Osteoporos Int 2008; 19:1777-1783.
44. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009; 20:2127-2134.
45. Schlenk EA, Bernardo LM, Organist LA, et al. Optimizing medication adherence in older patients: a systematic review. J Clin Outcomes Manag 2008; 15:595-606.
46. Shu AD, Stedman MR, Polinski JM, et al. Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care 2009; 15:417-424.
47. Solomon DH, Gleeson T, Iversen M, et al. A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial. Osteoporos Int 2010; 21:137-144.
48. Cotte FE, Fardellone P, Mercier F, et al. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010; 21:145-155.
49. Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 2009; 7:12-17.
50. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19:365-372.
51. Curtis JR, Westfall AO, Cheng H, et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 2008; 19:1613-1620.